Q2 EPS Estimates for UroGen Pharma Boosted by HC Wainwright

UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) - Stock analysts at HC Wainwright raised their Q2 2025 earnings per share (EPS) estimates for UroGen Pharma in a research report issued to clients and investors on Tuesday, May 13th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.75) for the quarter, up from their previous forecast of ($0.81). HC Wainwright currently has a "Buy" rating and a $55.00 target price on the stock. The consensus estimate for UroGen Pharma's current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for UroGen Pharma's Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($3.13) EPS, Q1 2026 earnings at ($0.44) EPS, Q3 2026 earnings at $0.22 EPS, Q4 2026 earnings at $0.51 EPS and FY2026 earnings at $0.27 EPS.

Several other equities research analysts also recently weighed in on URGN. Guggenheim reaffirmed a "buy" rating on shares of UroGen Pharma in a research report on Tuesday, April 29th. Scotiabank initiated coverage on UroGen Pharma in a research report on Wednesday, April 16th. They set a "sector outperform" rating and a $23.00 price target for the company. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a research note on Thursday, May 8th. The Goldman Sachs Group cut their target price on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. Finally, LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a report on Wednesday, February 19th. They set a "buy" rating and a $31.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, UroGen Pharma has an average rating of "Buy" and a consensus target price of $32.86.

UroGen Pharma Stock Performance

Shares of NASDAQ:URGN traded up $0.40 during midday trading on Thursday, reaching $8.37. The company's stock had a trading volume of 1,271,425 shares, compared to its average volume of 617,598. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The stock has a fifty day moving average of $10.53 and a 200 day moving average of $10.85. UroGen Pharma has a twelve month low of $6.46 and a twelve month high of $20.70. The firm has a market capitalization of $385.92 million, a PE ratio of -2.64 and a beta of 0.66.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The business had revenue of $20.25 million for the quarter, compared to the consensus estimate of $22.71 million.

Institutional Trading of UroGen Pharma

A number of institutional investors have recently made changes to their positions in the company. Barclays PLC lifted its holdings in UroGen Pharma by 409.3% in the 3rd quarter. Barclays PLC now owns 59,778 shares of the company's stock valued at $759,000 after purchasing an additional 48,040 shares in the last quarter. JPMorgan Chase & Co. boosted its position in UroGen Pharma by 263.1% during the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company's stock worth $864,000 after acquiring an additional 49,318 shares during the last quarter. Renaissance Technologies LLC acquired a new position in UroGen Pharma during the fourth quarter worth about $1,472,000. Bank of New York Mellon Corp grew its stake in UroGen Pharma by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company's stock valued at $1,001,000 after acquiring an additional 6,430 shares in the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new stake in UroGen Pharma in the 4th quarter valued at about $126,000. 91.29% of the stock is owned by institutional investors and hedge funds.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.